Daily Respiratory Research Analysis
Three papers advanced respiratory science across inflammation, fibrosis, and viral spillover. Epigenetic ‘training’ of epithelial IL-6 drives asthma exacerbations and is preventable by IL‑6 blockade in mice; collagen VII-mediated matrix stiffening emerges as an actionable driver of pleural fibrosis; and a single spike ‘630‑loop’ substitution in a bat sarbecovirus enhances ACE2 binding, suggesting alternative spillover pathways.
Summary
Three papers advanced respiratory science across inflammation, fibrosis, and viral spillover. Epigenetic ‘training’ of epithelial IL-6 drives asthma exacerbations and is preventable by IL‑6 blockade in mice; collagen VII-mediated matrix stiffening emerges as an actionable driver of pleural fibrosis; and a single spike ‘630‑loop’ substitution in a bat sarbecovirus enhances ACE2 binding, suggesting alternative spillover pathways.
Research Themes
- Epigenetic training and cytokine drivers of asthma exacerbations
- Mechanobiology of pleural fibrosis via extracellular matrix stiffening
- Spike conformational dynamics enabling coronavirus spillover
Selected Articles
1. Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations.
Across mouse, cell, and human epithelium, IL-6 was identified as a trained, central driver of asthma exacerbations. Neutralizing IL‑6 prevented experimental exacerbations, and IL6 hypomethylation in patient airway epithelium predicted higher expression and future exacerbations.
Impact: This work links epithelial epigenetic ‘training’ of IL-6 to exacerbation biology and demonstrates pharmacologic preventability in vivo, enabling biomarker-guided prevention strategies.
Clinical Implications: IL6 methylation and epithelial IL‑6 expression may stratify exacerbation-prone asthma, and targeted IL‑6 blockade or epithelial-focused interventions could prevent virus-triggered exacerbations.
Key Findings
- Intranasal anti‑IL‑6 completely prevented poly(I:C)-induced exacerbations in allergic asthma mice.
- Repeated poly(I:C) or RV16 exposure ‘trained’ IL6 upregulation in human bronchial epithelial cells.
- IL6 hypomethylation in airway epithelium associated with higher IL6 expression and future exacerbations in patient cohorts.
Methodological Strengths
- Triangulation across murine models, human epithelial cell systems, and independent human cohorts.
- Mechanistic intervention with IL‑6 neutralization demonstrating causality in vivo.
Limitations
- Poly(I:C) models mimic viral PAMPs but may not fully recapitulate diverse clinical viruses and comorbidities.
- Human cohort sizes are moderate and require broader validation; therapeutic IL‑6 targeting not yet tested clinically for exacerbation prevention.
Future Directions: Validate IL6 methylation/IL‑6 expression as predictive biomarkers in multicenter cohorts and test intranasal/airway-targeted IL‑6 blockade or epigenetic modulators to prevent viral-triggered exacerbations.
QUESTION: Epidemiological studies suggest that respiratory viral infections are major triggers of asthma exacerbations, and clinical studies have suggested the involvement of an increased interleukin-6 (IL-6) release. What is the pathophysiological role of IL-6 in asthma exacerbation, and which mechanisms lead to enhanced IL-6 release? MATERIALS AND METHODS: Exacerbations of ovalbumin-induced experimental allergic asthma were elicited in wild-type and IL-6-deficient mice by intranasal (i.n.) application of poly(I:C). Airway inflammation, cytokine expression and release, mucus production and airway hyperresponsiveness were measured. IL-6 was neutralised by i.n. anti-IL-6 antibody application. The human bronchial epithelial cell line, BEAS-2B, was stimulated with poly(I:C) and infected with human rhinovirus-16 in vitro, followed by quantification of IL6 gene expression and DNA methylation. Genome-wide DNA methylation was assessed in bronchial epithelial cells from adults with asthma (cohort I, n = 54) and in nasal epithelial cells from children and adults in the All-Age-Asthma cohort (ALLIANCE, n = 53 and n = 108 respectively). RESULTS: Poly(I:C)-induced experimental exacerbations in mice were preceded and paralleled by exaggerated IL-6 release in the airway epithelium, with IL-6 neutralisation completely preventing experimental exacerbations. Repetitive infection/stimulation with RV16 or poly(I:C) resulted in training of the IL-6 release in human respiratory epithelial cells. In patients, hypomethylation at the IL6 gene methylation was associated with high IL6 expression and future exacerbations. ANSWER: An exaggerated IL-6 release is required for exacerbation of experimental asthma, potentially the result of viral PAMP-induced immune training of airway epithelial cells. Additionally, patients with asthma carrying the epigenetic signature of a trained IL-6 response exacerbate more frequently. These findings open new avenues to identify and treat exacerbation-prone patients.
2. Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness.
Collagen VII is an early, upstream driver of pleural fibrosis. Mesothelial cell-specific Col7a1 deletion attenuated fibrosis, and excess collagen VII increased ECM stiffness to activate integrin/PI3K‑AKT/JUN signaling and feed-forward matrix deposition.
Impact: Identifies a mechanobiologic pathway (collagen VII→ECM stiffness→integrin signaling) as a tractable target for pleural fibrosis, shifting focus beyond collagen I/myofibroblasts.
Clinical Implications: Collagen VII may serve as an early biomarker and therapeutic target; integrin/PI3K‑AKT pathway inhibition or stiffness-modulating strategies could be explored for pleural fibrosis.
Key Findings
- Collagen VII is increased in human tuberculous pleural fibrosis and rises early in experimental models before collagen I and α‑SMA.
- Mesothelial cell-specific Col7a1 deletion (WT1‑Cre+; COL7A1flox/flox) attenuated pleural fibrosis in mice.
- Excess collagen VII increases ECM stiffness, activating integrin/PI3K‑AKT/JUN signaling and promoting further ECM deposition.
Methodological Strengths
- Integration of human tissue observations with mechanistic cell and conditional knockout mouse models.
- Causality demonstrated via mesothelial cell-specific genetic deletion and downstream pathway mapping.
Limitations
- Human data primarily from tuberculous pleural fibrosis; generalizability to other etiologies needs confirmation.
- No clinical interventional trials; translation of stiffness-targeting strategies remains to be tested in patients.
Future Directions: Validate collagen VII as a biomarker across pleural fibrosis etiologies; test integrin/PI3K‑AKT/JUN inhibitors and stiffness-modulating therapies in preclinical models and early-phase trials.
The interaction between cells and extracellular matrix (ECM) has been recognized in mechanism of fibrotic diseases. Collagen type VII (collagen VII) is an ECM component which plays an important role in cell-ECM interaction, particularly in cell anchoring and maintaining ECM integrity. Pleural mesothelial cells (PMCs) drive inflammatory reactions and ECM production in pleura. However, the role of collagen VII and PMCs in pleural fibrosis was poorly understood. In this study, collagen VII protein was found increase in pleura of patients with tuberculous pleural fibrosis. Investigation of cellular and animal models revealed that collagen VII began to increase at early stage in pleural fibrotic process. Increase of collagen VII occurred ahead of collagen I and α-SMA in PMCs and pleura of animal models. Inhibition of collagen VII by mesothelial cell-specific deletion of collagen VII gene (WT1-Cre+-COL7A1flox/flox) attenuated mouse experimental pleural fibrosis. At last, it was found that excessive collagen VII changed collagen conformation which resulted in elevation of ECM stiffness. Elevation of ECM stiffness activated integrin/PI3K-AKT/JUN signaling and promoted more ECM deposition, as well as mediated pleural fibrosis. In conclusion, excessive collagen VII mediated pleural fibrosis via increasing extracellular matrix stiffness.
3. Bat sarbecovirus WIV1-CoV bears an adaptive mutation that alters spike dynamics and enhances ACE2 binding.
A single ‘630‑loop’ substitution in WIV1‑CoV spike opens the trimer, enhances ACE2 recognition, and increases entry, providing a mechanistic alternative to reliance on a polybasic furin site for zoonotic adaptation. Trypsin pre-cleavage alleviates conformational constraints, implying evolutionary pressure to bypass S1–S2 cleavage limitations in bat hosts.
Impact: Reframes coronavirus spillover by pinpointing spike-opening substitutions as a parallel or precursor path to increased human tropism, informing surveillance and risk assessment.
Clinical Implications: Genomic surveillance should track ‘spike-opening’ substitutions (e.g., 630‑loop) in bat sarbecoviruses; risk models and countermeasures can incorporate entry-enhancing conformational changes beyond cleavage site acquisition.
Key Findings
- A single amino acid substitution in the S1 ‘630‑loop’ enhances spike opening, ACE2 binding, and cell entry in WIV1‑CoV.
- Trypsin pre-cleavage alleviates conformational constraints of SHC014‑CoV and Rs3367‑CoV spikes, suggesting spike-opening substitutions compensate for limited S1–S2 cleavage.
- Proposes alternative spillover scenarios where spike-opening substitutions precede or replace acquisition of a polybasic furin site.
Methodological Strengths
- Structure–function dissection across related sarbecovirus spikes with convergent mechanistic findings.
- Functional assays linking specific substitutions to receptor engagement and entry, plus protease pre-cleavage experiments.
Limitations
- Predominantly in vitro; in vivo pathogenicity and transmission impacts remain to be established.
- Cell culture adaptation complicates inference about ancestral sequences in nature.
Future Directions: Survey bat sarbecoviruses for spike-opening substitutions, test their phenotypes in human airway organoids/animal models, and integrate conformational metrics into zoonotic risk frameworks.
SARS-like betacoronaviruses (sarbecoviruses) endemic in bats pose a significant zoonotic threat to humans. Genetic pathways associated with spillover of bat sarbecoviruses into humans are incompletely understood. We previously showed that the wild-type spike of the rhinolophid bat coronavirus SHC014-CoV has poor entry activity and uncovered two distinct genetic pathways outside the receptor-binding domain (RBD) that increased spike opening, ACE2 binding, and cell entry. Herein, we show that the widely studied bat sarbecovirus WIV1-CoV is likely a cell culture-adapted variant whose progenitor bears a spike resembling that of Rs3367-CoV, which was sequenced from the same population of rhinolophid bats as SHC014-CoV. Our findings suggest that the acquisition of a single amino-acid substitution in the '630-loop' of the S1 subunit was the key spike adaptation event during the successful isolation of WIV1-CoV, and that it enhances spike opening, virus-receptor recognition, and cell entry in much the same manner as the substitutions we previously identified in SHC014-CoV using a pseudotype system. The conformational constraints on both the SHC014-CoV and Rs3367-CoV spikes could be alleviated by pre-cleaving them with trypsin, suggesting that the spike-opening substitutions arose to circumvent the lack of S1-S2 cleavage. We propose that the 'locked-down' nature of these spikes and their requirement for S1-S2 cleavage to engage ACE2 represent viral optimizations for a fecal-oral lifestyle and immune evasion in their natural hosts. These adaptations may be a broader property of bat sarbecoviruses than currently recognized. The acquisition of a polybasic furin cleavage site at the S1-S2 boundary is accepted as a key viral adaptation for SARS-CoV-2 emergence that overcame a host protease barrier to viral entry in the mammalian respiratory tract. Our results suggest alternative spillover scenarios in which spike-opening substitutions that promote virus-receptor binding and entry could precede, or even initially replace, substitutions that enhance spike cleavage in the zoonotic host.